Echinoside A, a new marine-derived anticancer saponin, targets topoisomerase2α by unique interference with its DNA binding and catalytic cycle

Annals of Oncology

Volumn 21, Issue 3, 2009, Pages 597-607

  Li, M ^a   Miao, Z H ^a   Chen, Z ^a   Chen, Q ^a   Gui, M ^a   Lin, L P ^a   Sun, P ^b   Yi, Y H ^b   Ding, J ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Catalytic cycle; DNA damage; Echinoside A; Marine derived anticancer drugs; Topoisomerase2 inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA; ECHINOSIDE A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA BINDING; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN TARGETING; XENOGRAFT;

EID: 77949650539     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp335     Document Type: Article

References (37)

1. Newman DJ, Cragg GM. Marine natural products and related compounds in clinical and advanced preclinical trials. J Nat Prod 2004; 67: 1216-1238.
2. Brana MF, Cacho M, Gradillas A et al. Intercalators as anticancer drugs. Curr Pharm Des 2001; 7: 1745-1780.
3. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351-375.
4. Azarova AM, Lyu YL, Lin CP et al. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A 2007; 104: 11014-11019.
5. Skehan P, Storeng R, Scudiero D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112.
6. Huang M, Gao H, Chen Y et al. Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo. Clin Cancer Res 2007; 13: 1298-1307.
7. Steinfelder HJ, Quentin I, Ritz V. A fast and sensitive technique to study the kinetics and the concentration dependencies of DNA fragmentation during drug-induced apoptosis. J Pharmacol Toxicol Methods 2000; 43: 79-84.
8. Yuan S, Zhang X, Lu L et al. Anticancer activity of methoxymorpholinyl doxorubicin (PNU 152243) on human hepatocellular carcinoma. Anticancer Drugs 2004; 15: 641-646.
9. Tanabe K, Ikegami Y, Ishida R et al. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 1991; 51: 4903-4908.
10. Qin Y, Meng L, Hu C et al. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain. Mol Cancer Ther 2007; 6: 2429-2440.
11. Meng LH, Zhang JS, Ding J. Salvicine, a novel DNA topoisomerase II inhibitor, exerting its effects by trapping enzyme-DNA cleavage complexes. Biochem Pharmacol 2001; 62: 733-741.
12. Osheroff N, Zechiedrich EL. Calcium-promoted DNA cleavage by eukaryotic topoisomerase II: trapping the covalent enzyme-DNA complex in an active form. Biochemistry 1987; 26: 4303-4309.
13. Antony S, Agama KK, Miao ZH et al. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res 2007; 67: 10397-10405.
14. Yamashita Y, Fujii N, Murakata C et al. Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry 1992; 31: 12069-12075.
15. Perrin D, van Hille B, Barret JM et al. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action. Biochem Pharmacol 2000; 59: 807-819.
16. Fortune JM, Osheroff N. Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage. J Biol Chem 1998; 273: 17643-17650.
17. Jensen LH, Thougaard AV, Grauslund M et al. Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors. Cancer Res 2005; 65: 7470-7477.
18. Hu CX, Zuo ZL, Xiong B et al. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket. Mol Pharmacol 2006; 70: 1593-1601.
19. Dong KC, Berger JM. Structural basis for gate-DNA recognition and bending by type IIA topoisomerases. Nature 2007; 450: 1201-1205.
20. Accelrys. 2000 edition. San Diego, CA: Accelrys Inc 2000.
21. Raby BA, Lazarus R, Silverman EK et al. Association of vitamin D receptor gene polymorphisms with childhood and adult asthma. Am J Respir Crit Care Med 2004; 170: 1057-1065.
22. Tripos. 6.8 edition. St. Louis, MO: Tripos Inc 2001.
23. Singh NP, McCoy MT, Tice RR et al. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988; 175: 184-191.
24. Lu HR, Zhu H, Huang M et al. Reactive oxygen species elicit apoptosis by concurrently disrupting topoisomerase II and DNA-dependent protein kinase. Mol Pharmacol 2005; 68: 983-994.
25. Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007; 446: 749-757.
26. Xiao H, Huang B, Yuan Y et al. Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res 2007; 13: 1823-1830.
27. Wang J, Chen C, Li B et al. Antioxidative function and biodistribution of [Gd@C82(OH)22]n nanoparticles in tumor-bearing mice. Biochem Pharmacol 2006; 71: 872-881.
28. Montecucco A, Pedrali-Noy G, Spadari S et al. DNA unwinding and inhibition of T4 DNA ligase by anthracyclines. Nucleic Acids Res 1988; 16: 3907-3918.
29. Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 2000; 64: 221-253.
30. Wilstermann AM, Osheroff N. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr Top Med Chem 2003; 3: 321-338.
31. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007; 70: 461-477.
32. Le Tourneau C, Raymond E, Faivre S. Aplidine: a paradigm of how to handle the activity and toxicity of a novel marine anticancer poison. Curr Pharm Des 2007; 13: 3427-3439.
33. Kim D, Lee IS, Jung JH et al. Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells. Anticancer Res 1999; 19: 4085-4090.
34. Ahn MY, Jung JH, Na YJ et al. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol Oncol 2008; 108: 27-33.
35. Larsen AK, Escargueil AE, Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 2003; 99: 167-181.
36. Boehm HJ, Boehringer M, Bur D et al. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J Med Chem 2000; 43: 2664-2674.
37. Robinson MJ, Corbett AH, Osheroff N. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II. Biochemistry 1993; 32: 3638-3643.